TYRA — Tyra Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $823.05m
- $619.58m
- 43
- 22
- 70
- 41
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 3.12 | 9.3 | 26.3 | 58.9 | 79.9 |
Operating Profit | -3.12 | -9.3 | -26.3 | -58.9 | -79.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.07 | -9.34 | -26.3 | -55.3 | -69.1 |
Net Income After Taxes | -4.07 | -9.34 | -26.3 | -55.3 | -69.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.07 | -9.34 | -26.3 | -55.3 | -69.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.07 | -9.34 | -26.3 | -55.3 | -69.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.103 | -0.237 | -0.634 | -1.32 | -1.62 |
Dividends per Share |